Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $3.6 million.

  • Gyre Therapeutics' Net Income towards Common Stockholders rose 22117.44% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 10748.8%. This contributed to the annual value of $12.1 million for FY2024, which is 11300.4% up from last year.
  • Gyre Therapeutics' Net Income towards Common Stockholders amounted to $3.6 million in Q3 2025, which was up 22117.44% from $442000.0 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Net Income towards Common Stockholders high stood at $51.6 million for Q2 2022, and its period low was -$101.0 million during Q4 2023.
  • Over the past 5 years, Gyre Therapeutics' median Net Income towards Common Stockholders value was $442000.0 (recorded in 2025), while the average stood at -$8.4 million.
  • In the last 5 years, Gyre Therapeutics' Net Income towards Common Stockholders tumbled by 45361.46% in 2021 and then skyrocketed by 35909.27% in 2022.
  • Gyre Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$20.3 million in 2021, then tumbled by 47.27% to -$29.9 million in 2022, then plummeted by 237.7% to -$101.0 million in 2023, then skyrocketed by 99.9% to -$99000.0 in 2024, then surged by 3746.46% to $3.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at $3.6 million for Q3 2025, versus $442000.0 for Q2 2025 and $2.7 million for Q1 2025.